SeqOne unlocks the power of Illumina’s TruSightTM Oncology 500
With the addition of the TSO500 pan-cancer NGS assay for genomic profiling of tumour samples, SeqOne now provides oncologists with the most comprehensive genomic data analytics solution for fast, actionable results.
SeqOne offers a powerful genomic analysis platform capable of detecting the complex variants that are critical to cancer diagnosis and treatment.
Get in touch and find out how SeqOne can provide more actionable insights from your genomics data contact@seqone.com.
Similar readings
-
News17 March 2023
SeqOne Genomics appoints Hervé Pouzoullic as Chief Commercial Officer
A seasoned leader in the pharmaceutical and diagnostics industry, specialized in structuring international healthcare sales joins the team to accelerate international expansion Montpellier, March 14 [...]
-
News Press release
22 February 2023
SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors. SeqOne’s test simplifies the deployment of this test while [...]
-
News Platform features Press release Science
9 February 2023
SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
Montpellier, February 9th, 2023: SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving [...]
